Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ceapro Inc. stock logo
CRPOF
Ceapro
$0.17
$0.17
$0.11
$0.40
$13.31M1.4715,466 shsN/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
$0.05
+1.6%
$0.05
$0.13
$0.38
$23.46M1.33338,444 shs16,565 shs
NVLNF
Novelion Therapeutics
$0.70
-1.2%
$0.70
$0.51
$1.00
$13.77M2.15261,364 shs26,900 shs
TAOX
Synaptogenix
$8.40
-8.6%
$0.00
$1.84
$11.98
$11.67M1.87287,951 shs249,502 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ceapro Inc. stock logo
CRPOF
Ceapro
0.00%0.00%0.00%0.00%0.00%
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
+15.29%+6.88%+5.87%-2.46%+145.74%
NVLNF
Novelion Therapeutics
0.00%0.00%0.00%0.00%0.00%
TAOX
Synaptogenix
0.00%+36.36%+839,999,900.00%+839,999,900.00%+839,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/AN/AN/AN/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NVLNF
Novelion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
TAOX
Synaptogenix
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ceapro Inc. stock logo
CRPOF
Ceapro
0.00
N/AN/AN/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
0.00
N/AN/AN/A
NVLNF
Novelion Therapeutics
0.00
N/AN/AN/A
TAOX
Synaptogenix
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ceapro Inc. stock logo
CRPOF
Ceapro
$7.14M1.86$0.06 per share2.74$0.32 per share0.53
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
NVLNF
Novelion Therapeutics
$130.43M0.11N/AN/A($4.69) per share-0.15
TAOX
Synaptogenix
N/AN/AN/AN/A$4.33 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ceapro Inc. stock logo
CRPOF
Ceapro
-$3.49M-$0.06N/AN/A-69.60%-20.30%-18.07%N/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
-$6.64MN/A0.00N/AN/AN/A-64.66%-42.92%N/A
NVLNF
Novelion Therapeutics
-$108.33MN/A0.00N/AN/AN/AN/AN/A
TAOX
Synaptogenix
-$12.77M-$20.16N/AN/AN/A-359.08%-153.14%N/A

Latest MATN, NVLNF, CRPOF, and TAOX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2025Q2 2025
TAOX
Synaptogenix
N/A-$11.26N/A-$11.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/AN/AN/AN/AN/A
NVLNF
Novelion Therapeutics
N/AN/AN/AN/AN/A
TAOX
Synaptogenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
11.00
7.72
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/A
0.17
0.17
NVLNF
Novelion Therapeutics
N/AN/AN/A
TAOX
Synaptogenix
N/A
72.59
72.59

Institutional Ownership

CompanyInstitutional Ownership
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
0.07%
NVLNF
Novelion Therapeutics
48.64%
TAOX
Synaptogenix
10.34%

Insider Ownership

CompanyInsider Ownership
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
39.22%
NVLNF
Novelion Therapeutics
3.60%
TAOX
Synaptogenix
2.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A78.29 millionN/ANot Optionable
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
1390.24 millionN/ANot Optionable
NVLNF
Novelion Therapeutics
10919.62 millionN/ANot Optionable
TAOX
Synaptogenix
41.39 million1.35 millionN/A

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

Ceapro stock logo

Ceapro OTCMKTS:CRPOF

$0.17 0.00 (0.00%)
As of 06/6/2024

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

Mateon Therapeutics stock logo

Mateon Therapeutics OTCMKTS:MATN

$0.05 +0.00 (+1.60%)
As of 08/15/2025

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

Novelion Therapeutics OTCMKTS:NVLNF

$0.70 -0.01 (-1.20%)
As of 01/16/2020

Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Synaptogenix NASDAQ:TAOX

$8.40 -0.79 (-8.60%)
As of 08/15/2025 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.